Post by NEMERA

Ensuring bio-based materials meet pharmaceutical regulatory requirements Sustainability only works if regulatory robustness comes first. To develop the bio-based version of Novelia®, our approach relies on a mass balance methodology and certified supply chains, as fully stabilized 100% bio-based content is not yet achievable at scale. Today, bio-based resins offer the best balance between environmental progress and regulatory feasibility within the current pharmaceutical framework. For our partners, a major advantage is that the bio-based version of Novelia® can be used for products already on the market, together with the ISCC+ certificate we provide, without the need to file a new marketing authorization application for a faster implementation, reduced regulatory risk, and tangible environmental impact. Learn more about our ophthalmic solutions : urlr.me/5csTqG